Global Pasireotide Market Size By Type (0.3mg/ml, 0.6mg/ml), By Application (Hospital, Pharmacy), By Region, And Segment Forecasts, 2023 to 2032

The Global Pasireotide Market was valued at USD 365 million in 2023 and is projected to reach USD 612 million by 2031, growing at a CAGR of 6.6% during the forecast period from 2023 to 2031. Pasireotide, a somatostatin analog, is widely used in the treatment of Cushing’s disease and acromegaly. The market growth is driven by increasing prevalence of endocrine disorders, rising awareness regarding rare disease management, and advancements in drug delivery mechanisms. The increasing use of pasireotide as a second-line treatment for patients unresponsive to surgery, along with robust research in hormone-targeted therapies, continues to fuel global demand.

Drivers:

1. Rising Incidence of Endocrine Disorders:

A surge in endocrine diseases such as Cushing’s disease and acromegaly, especially in aging populations, is driving the demand for pasireotide as a long-term therapeutic solution.

2. Growing Awareness of Rare Disease Treatments:

Global health initiatives promoting awareness and treatment of rare diseases are positively impacting the adoption of pasireotide, particularly in developed markets.

3. Advancements in Drug Formulations:

The development of long-acting pasireotide formulations has enhanced patient compliance and expanded therapeutic applications, contributing to market growth.

Restraints:

1. High Cost of Therapy:

Pasireotide is associated with high treatment costs, which can limit accessibility in lower-income and developing regions, thereby restraining market expansion.

2. Side Effects and Safety Concerns:

Common side effects such as hyperglycemia, gastrointestinal discomfort, and gallstones raise safety concerns, potentially limiting its prescription in certain patient populations.

Opportunity:

1. Expansion into Emerging Markets:

Improving healthcare infrastructure and increased investments in rare disease diagnostics across Asia-Pacific and Latin America provide untapped opportunities for market penetration.

2. Clinical Research in New Indications:

Ongoing clinical studies investigating pasireotide for other pituitary and hormonal disorders offer new growth avenues, with potential label expansions likely to benefit the market.

Market by System Type Insights:

By formulation, long-acting release (LAR) pasireotide dominated the market in 2023. The once-monthly injectable form offers increased convenience and adherence compared to short-acting formulations. LAR continues to be the preferred option among endocrinologists due to its effectiveness in sustained hormone suppression.

Market by End-use Insights:

Hospitals represented the largest end-use segment in 2023, accounting for over 50% of total market revenue. Hospitals lead in prescribing and administering pasireotide due to the need for specialist supervision. Specialty clinics are expected to see the highest growth due to increased outpatient treatments and patient follow-ups.

Market by Regional Insights:

North America led the global pasireotide market in 2023, driven by high disease awareness, reimbursement support, and advanced healthcare infrastructure. Meanwhile, Asia-Pacific is expected to register the highest CAGR during the forecast period due to increasing diagnosis rates and expanding pharmaceutical access across developing countries like China and India.

Competitive Scenario:

Key players operating in the Global Pasireotide Market include Novartis AG, Ipsen, Recordati S.p.A., and Sun Pharmaceutical Industries Ltd. These companies are focusing on clinical trials, patent extensions, and strategic alliances to strengthen their market position.

In 2023, Novartis AG continued global distribution of Signifor® LAR, expanding into emerging markets.

In 2024, Recordati launched efforts to co-develop combination therapies involving pasireotide for broader endocrine applications.

Ipsen announced clinical collaborations aimed at investigating pasireotide in the treatment of neuroendocrine tumors.

Scope of Work – Global Pasireotide Market

Key Market Developments:

Nov 2023: Novartis AG received FDA approval for expanded labeling of pasireotide in pediatric Cushing's disease treatment.

Jan 2024: Ipsen initiated Phase II trials combining pasireotide with cabergoline for treating resistant acromegaly cases.

Mar 2024: Sun Pharma entered into licensing agreement to market pasireotide biosimilars in Southeast Asia.

FAQs:

1) What is the current market size of the Global Pasireotide Market?

The market was valued at USD 365 million in 2023.

2) What is the major growth driver of the Global Pasireotide Market?

The major growth driver is the rising incidence of endocrine disorders and growing preference for long-acting formulations.

3) Which is the largest region during the forecast period in the Global Pasireotide Market?

North America remains the largest region, while Asia-Pacific is projected to grow the fastest.

4) Which segment accounted for the largest market share in the Global Pasireotide Market?

The long-acting pasireotide formulation segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Pasireotide Market?

Key players include Novartis AG, Ipsen, Recordati S.p.A., and Sun Pharmaceutical Industries Ltd.